Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
During the Phase 1 and Phase 2 portions of the study, participant eligibility criteria are identical except for prior treatment for anaplastic thyroid cancer (ATC). During Phase 1, eligible participants may have received prior chemotherapy while during Phase 2, eligible participants must be chemotherapy naïve.~Inclusion Criteria:~* Histologically or cytologically diagnosed, advanced ATC~* Measurable lesion(s)~* Lesion(s) (primary or metastatic) with viable tumor tissue accessible for repeated biopsy~* Age equal to or older than 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~* Adequate organ and bone marrow function~* Agreement to use effective contraception while on treatment and for equal to or greater than 3 months after end of treatment~* Pregnant or breastfeeding~Exclusion Criteria:~* Medical history of diabetes mellitus requiring treatment with insulin or oral agents; no pleural or pericardial effusion or clinically significant pulmonary or cardiovascular disease.~* Clinically active brain metastasis, uncontrolled seizure disorder, spinal cord compression, or carcinomatous meningitis~* Clinically significant active infection requiring antibiotic or antiretroviral therapy~* Concomitant use of other thiazolidinediones (TZDs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1; 0.15 mg CS-7017 (Type: EXPERIMENTAL): Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 \[Dose Level 1a\] or 175 \[Dose Level 1b\] mg/m\^2 intravenous (IV) paclitaxel once every 3 weeks.
- Cohort 2; 0.30 mg CS-7017 (Type: EXPERIMENTAL): Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m\^2 IV paclitaxel once every 3 weeks.
- Cohort 3; 0.50 mg CS-7017 (Type: EXPERIMENTAL): Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m\^2 IV paclitaxel once every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).